A new study led by the Baltimore based researcher Dr. Rehan Qayyum has revealed that the synthetic version of the human insulin is equally good for the type 2 diabetes.In an interview to the Reuters, Dr. Rehan Qayyum from Johns Hopkins Hospital, said,
“There is no difference between premixed human insulin and premixed insulin analogues.”
The study, published in the Annals of Internal Medicine finds that the Premixed insulin analogues provided tighter glucose control than long-acting insulin and non-insulin agents, according to the investigators’ report in the Annals of Internal Medicine. Premixed insulin analogues were comparable to premixed human insulin in lowering A1C levels, an indicator of relatively long-term glucose control.
The occurrence of episodes of too-low glucose levels, i.e., hypoglycemia, was similar with premixed insulin analogues and with premixed human insulin.
It can be added that the insulin analog is an altered form of insulin different from any occurring in nature, but still available to the human body for performing the same action as human insulin in terms of glycemic control. Through genetic engineering of the underlying DNA, amino acid sequence of insulin can be changed to alter its ADME (absorption, distribution, metabolism, and excretion) characteristics.
These modifications have been used to create two types of insulin analogs: those that are more readily absorbed from the injection site and therefore act faster than natural insulin injected subcutaneously, intended to supply the bolus level of insulin needed after a meal; and those that are released slowly over a period of between 8 and 24 hours, intended to supply the basal level of insulin for the day.
However, researchers also told that much research work is required to determine whether the effects are sustainable long term.